Bleeding Disorders Treatment Market Overview
The bleeding disorder treatment industry is largely bolstered by the expanding patient pool, mounting awareness about the available treatment options, and the supportive compensation policies. Expiry of patents belonging to major brands can also present opportunities to generic drug manufacturers to make their foray into the bleeding disorder therapeutics market. the demand for bleeding disorder treatment options is quite robust in western economies in Europe and North America, in view of the exorbitant rates of the branded drugs. The demand for low-priced drugs is growing in developing and underdeveloped countries, given the reduced purchasing capacity of the patients in terms of medical treatment. Bleeding disorders result in susceptibility to bleeding due to faulty blood clotting, caused by defect in the blood coagulation. Bleeding disorders treatment includes the drugs used in the treatment and management of such bleeding disorders. The global bleeding disorders treatment market is continually growing owing to the prevalence of bleeding disorders such as hemophilia, platelet disorders, Von Willebrand disease and others.
According to Market Research Future (MRFR), the globalBleeding Disorders Treatment Market Size is expected to garner a CAGR of over 10.90% over the assessment period (2022-2030). The demographic drivers of the market include the growing incidence of bleeding disorders and the growing population. According to the National Hemophilia Foundation hemophilia affects about 20,000 people in the United States and more than 400,000 people globally. Platelet disorders have an incidence of 1900to 6400 per 10000a year.
The economic driving factors include the growing per capita income and healthcare expenditure as percent of GDP. The psychotropic drivers of the market include the increasing awareness of bleeding disorders. The market is also expected to rise due to growth in the diagnosis rate owing to development of healthcare infrastructure and government initiatives such ascompulsory screening which is complementing the market growth. Expired patents for existing brands should also give generic drug companies the opportunity to enter the lucrative market. The market is mainly focused on western European countries and North America due to the high prices of branded medicines. The low cost of medicines will allow market penetration in developing and underdeveloped countries where patients cannot afford expensive drugs. As a result, availability of affordable generic drugs is likely to stimulate market growth in the regions.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6592
Bleeding Disorders Treatment Market Segmentation
The report is segmented into five dynamics to widen the scope of understanding,
By Type : Hemophilia A, Hemophilia B, Von Willebrand Disease (vWD), among others.
By Drug Class : Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrate, among others.
By Treatment : Medication, Desmopressin (DDAVP), Hormone replacement therapy, Contraceptives, Anti-fibrinolytic/clot-stabilizing drugs, Fibrin sealants, Drugs applied to cuts, among others.
By End-users : Hospitals, Clinics, Research Institutes, among others.
By Regions : North America, Europe, Asia Pacific, and the Rest-of-the-World.
Bleeding Disorders Treatment Market Regional Analysis
The regions across which the global market is spread across include Europe, the Americas, MEA or Middle East and Africa and Asia Pacific or APAC.
North America will be positioned in the lead over the review period, remarks MRFR, considering the fast adoption rate of modern medical technologies and the soaring number of companies specializing in drug development. Also, the surge in FDA approvals is encouraging players to focus even more on extensive R&D of highly advanced drugs and other treatment lines, which is bound to favor the bleeding disorders treatment market in the ensuing years.
Studies confirm that close to 149,764 people in Europe had hemophilia A and nearly 10,811 of the overall population in the region were diagnosed with platelet disorders in 2016. These statistics indicate the significant growth potential of the bleeding disorders treatment market, as a result of which the region is touted to secure the second position in the following years. Other encouraging factors include the increase in research spending, technical innovations and the general fall in human health across the region. The enhanced need for efficient and advanced therapies and drugs for treating hemophilia also push the market expansion rate in the region.
Bleeding Disorders Treatment Market Players
- Shire Plc
- Pfizer Inc.
- Bayer Pharmaceuticals
- Biogen Inc.
- BDI Pharma
- CSL Behring
- Grifols
- Sun Pharmaceutical Industries Ltd.
- Octapharma
- Ferring Pharmaceuticals
- Novo Nordisk A/S
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
